National 2021 | Diabetes on the Net

Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

Book your place for our upcoming virtual conference

18-19 November 2021

17th National Conference of the

Primary Care Diabetes Society (PCDS)

We are delighted to invite you to virtually attend this year’s National Conference of the Primary Care Diabetes Society (PCDS), our annual, free-to-attend, two-day virtual conference taking place on 18-19 November 2021.

While the format remains virtual this year, you will, as ever, be able to benefit from clinically focused education on a range of topics that are most relevant to the practicalities of managing diabetes in primary care today. To name just a few of these, we have experts presenting on mental health, retinopathy, insulin initiation, the diabetic foot, and the all-important new ways-of-working.

We very much hope that you can join us for this key event in the 2021 diabetes calendar.

This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more

  • Ask the experts your burning questions through the LIVE Q&A at the end of each session
  • Log on anytime during the two-days from the comfort of your own home to view the sessions
  • Don’t worry if you miss something, all of the content will be available on-demand
  • Claim 11 CPD points for the two-day virtual conference

Agenda

Day 1

09.15-09.25

Session 1

Chair’s introduction

09.25-09.55

COVID-19 and diabetes: Latest evidence

15 min break

10.10-10.40

Symposia

15 min break

10.55-11.25

Addressing health inequality in a multi-ethnic population

15 min break

11.40-12.20

Session 2

‘In Practice’ masterclasses Rotation 1

1. Severe mental illness and learning difficulties

2. Older and frail people

3. Sexual health

4. Foot care and peripheral arterial disease

15 min break

12.35-13.05

Symposia

15 min break

13.20-14.00

Rotation 2

1. Severe mental illness and learning difficulties

2. Older and frail people

3. Sexual health

4. Foot care and peripheral arterial disease

15 min break

14.15-14.45

Session 3

Language matters: Overcoming common communication hurdles

15 min break

15.00-15.30

Symposia

15 min break

15.45-16.15

Question Time: Individualised lifestyle interventions

16.15-16.45

AGM session

16.45

Chair’s close

Day 2

09.00-09.10

Session 1

Chair’s introduction

09.10-09.40

Individualised care in the context of multimorbidity

15 min break

09.55-10.25

Symposia

15 min break

10.40-11.10

Connecting the dots in the obesity pathway

15 min break

11.25-12.05

Session 2

‘In Practice’ masterclasses Rotation 1

1. Top tips for primary care

  • Retinopathy
  • Liver disease
  • Renal impairment

2. Insulin initiation and titration: complex cases

3. Getting primary care back on the road: diabetes care post-COVID-19

4. ‘In association’ masterclass

15 min break

12.20-13.00

Rotation 2

1. Top tips for primary care

  • Retinopathy
  • Liver disease
  • Renal impairment

2. Insulin initiation and titration: complex cases

3. Getting primary care back on the road: diabetes care post-COVID-19

15 min break

13.15-13.45

Session 3

Younger people: Everything you need to know in primary care

15 min break

14.00-14.30

Symposia

15 min break

14.45-15.15

Diabetes Distilled

15.15-15.25

Chair’s concluding remarks

Speakers

Sarah-N-Ali (002)

Sarah Ali

Consultant Diabetologist, Royal Free London NHS Foundation Trust

Peter-Bagshaw_SQ.jpg

Peter Bagshaw

Clinical Lead in Dementia and Mental Health, South Glos CCG, and Director of the South West Clinical Network for Dementia

F_Place.png

Melissa Blow

Clinical Lead Podiatrist in Diabetes and Tissue Viability, Aneurin Bevan UHB

Pam_CRL.png

Pam Brown

GP, Swansea

Mark-Davies_1.png

Mark Davies

Consultant Clinical Psychologist, Belfast Health and Social Care Trust

Sarah-Davies_cropped.jpg

Sarah Davies

GP Partner, Cardiff

Jane-Diggle.png

Jane Diggle

Specialist Practitioner Practice Nurse, South Kirkby

Su_Down.png

Su Down

Diabetes Nurse Consultant, Somerset

Dr-Kevin-Fernando.jpg

Kevin Fernando

GPwSI in Diabetes and Medical Education, North Berwick

Claire_CRL.png

Clare Hambling

GP, Norfolk, and Chair of the PCDS

Lesley-Hamilton.png

Lesley Hamilton

Diabetes Dietitian and Diabetes Network Manager, Western Trust

Patrick-Holmes.jpg

Patrick Holmes

GP, Darlington

Naresh-Kanumilli-e1599055204247.png

Naresh Kanumilli

GP with Specialist Interest in Diabetes and Clinical Network Lead for Diabetes, Manchester

Kamlesh-Khunti.png

Kamlesh Khunti

Professor of Primary Care Diabetes and Vascular Medicine, Leicester

Stephen_Lawrence.png

Stephen Lawrence

GPSI, Kent and Associate Clinical Professor, Warwick University Medical School

David_CRL.png

David Millar-Jones

GPwI in Diabetes, Cwmbran

Nicola.png

Nicola Milne

Community Diabetes Specialist Nurse, Manchester

Sam-Seidu_SQ.jpg

Sam Seidu

GP Partner, Leicester

Abd-Tahrani_SQ.jpg

Abd Tahrani

Research Training Fellow and Clinical Lecturer in Diabetes and Endocrinology, Birmingham

Sanjay_Tanna.png

Sanjay Tanna

Lead Clinical Pharmacist, Blackpool

Conference sponsors

GOLD SPONSOR

Boehringer Ingelheim and Lilly Diabetes Alliance

In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centres on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical needs

SILVER SPONSOR

Abbott’s Diabetes Care Division

Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, there were 201 trials at 376 centres in the UK, involving over 7,000 patients. For more information, please visit www.astrazeneca.co.uk

Eli Lilly and Company Ltd​

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world.

For more information, visit www.lillydiabetes.co.uk

Novo Nordisk

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.

Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.

For more information visit www.novonordisk.co.uk

MASTERCLASS SPONSOR

Abbott’s Diabetes Care Division

Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk

BRONZE SPONSOR

Novo Nordisk

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products. For more information visit www.novonordisk.co.uk

Taking place on:

This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.